HomeInsightsStock Comparison

Cipla Ltd vs Strides Pharma Science Ltd Stock Comparison

Cipla Ltd vs Strides Pharma Science Ltd Stock Comparison

Last Updated on: Jun 04, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1472 as of 03 Jun 15:30.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 29.3 on March 2024 . This represents a CAGR of 5.90% over 5 yearsThe P/E Ratio of Strides Pharma Science Ltd changed from 79.4 on March 2020 to 0 on March 2024 . This represents a CAGR of -100.00% over 5 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 120673 crore on March 2024 . This represents a CAGR of 28.75% over 5 yearsThe Market Cap of Strides Pharma Science Ltd changed from ₹ 2888 crore on March 2020 to ₹ 7192 crore on March 2024 . This represents a CAGR of 20.01% over 5 years.
  • The revenue of Cipla Ltd for the Mar '25 is ₹ 7019 crore as compare to the Dec '24 revenue of ₹ 7294 crore. This represent the decline of -3.78% The revenue of Strides Pharma Science Ltd for the Mar '25 is ₹ 1205 crore as compare to the Dec '24 revenue of ₹ 1160 crore. This represent the growth of 3.9%.
  • The ebitda of Cipla Ltd for the Mar '25 is ₹ 1827 crore as compare to the Dec '24 ebitda of ₹ 2210 crore. This represent the decline of -17.35% The ebitda of Strides Pharma Science Ltd for the Mar '25 is ₹ 205.56 crore as compare to the Dec '24 ebitda of ₹ 214.45 crore. This represent the decline of -4.15%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1225 crore over 8 quarters. This represents a CAGR of 10.87% The net profit of Strides Pharma Science Ltd changed from ₹ -9.36 crore to ₹ 85.62 crore over 8 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.74 % on March 2024 . This represents a CAGR of 12.57% over 5 yearsThe Dividend Payout of Strides Pharma Science Ltd changed from 104.26 % on March 2020 to 35.08 % on March 2024 . This represents a CAGR of -19.58% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Limited is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Strides Pharma Science Ltd

  • Strides Pharma Science Limited is a global pharmaceutical company headquartered in Bengaluru, India.
  • The Company mainly operates in the regulated markets including key markets of US, Europe, Australia, South Africa.
  • It has presence in the emerging markets largely in Africa where it has a branded business and is a pre qualified supplier to donor-funded programme though their institutional business. The Company is an integrated manufacturer and exporter of Finished Pharmaceutical Dosage forms for both branded and generic.
  • It manufactures a very wide spectrum of ethical pharmaceutical products, OTC products and nutraceuticals.
  • Their dosage forms range includes tablets, capsules, soft gelatin capsules, parenterals and semisolids.

Cipla Ltd News Hub

News

Jay Precision Pharmaceuticals acquires 26% stake in AMPIN Energy C&I Eighteen

Jay Precision Pharmaceuticals, subsidiary of Cipla, has completed acquisition of 26% stake...

Read more

29 May 2025 18:48

News

Cipla announced incorporation of subsidiary - CiplaRna GmbH' in Germany

Cipla announced that Cipla (EU), UK, a wholly owned subsidiary of the Company, has incorpo...

Read more

29 May 2025 18:50

News

Cipla to convene AGM

Cipla announced that the 89th Annual General Meeting(AGM) of the company will be held on 1...

Read more

14 May 2025 15:08

News

Board of Cipla recommends final dividend

Cipla announced that the Board of Directors of the Company at its meeting held on 13 May 2...

Read more

13 May 2025 14:34

News

Board of Cipla recommends special dividend

Cipla announced that the Board of Directors of the Company at its meeting held on 13 May 2...

Read more

13 May 2025 14:34

News

Cipla registers PAT of Rs 1,222 crore in Q4; EBITDA margin rises to 22.8%

On the segmental front, the company's India business revenue was Rs 2,622 crore (up 8% YoY...

Read more

13 May 2025 15:17

Strides Pharma Science Ltd News Hub

News

Board of Strides Pharma Science recommends final dividend

Strides Pharma Science announced that the Board of Directors of the Company at its meeting...

Read more

22 May 2025 18:03

News

Strides Pharma Science to announce Quarterly Result

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 22 ...

Read more

17 May 2025 11:40

News

Strides Pharma's US arm acquires four drugs to bolster portfolio

The portfolio consists of liquids and immediate release solid orals which are in the thera...

Read more

30 Apr 2025 07:51

News

Strides Pharma Science announces incorporation of step-down subsidiary

Arco Lab, a wholly owned subsidiary of Strides Pharma Science has incorporated a new wholl...

Read more

11 Apr 2025 15:34

News

Strides Pharma Science announces acquisition of Singapore-based Amexel

Strides Pharma Global (SPG), a step-down wholly-owned subsidiary of Strides Pharma Science...

Read more

15 Mar 2025 15:45

News

Strides Pharma Science appoints director

Strides Pharma Science has appointed Mukta Arora (DIN: 07225715) as Independent Director o...

Read more

31 Jan 2025 10:49

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Strides Pharma Science Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Strides Pharma Science Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Strides Pharma Science Ltd

Which company has a larger market capitalization, Cipla Ltd or Strides Pharma Science Ltd?

Market cap of Cipla Ltd is 118,949 Cr while Market cap of Strides Pharma Science Ltd is 7,278 Cr

What are the key factors driving the stock performance of Cipla Ltd and Strides Pharma Science Ltd?

The stock performance of Cipla Ltd and Strides Pharma Science Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Strides Pharma Science Ltd?

As of June 4, 2025, the Cipla Ltd stock price is INR ₹1472.8. On the other hand, Strides Pharma Science Ltd stock price is INR ₹789.75.

How do dividend payouts of Cipla Ltd and Strides Pharma Science Ltd compare?

To compare the dividend payouts of Cipla Ltd and Strides Pharma Science Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions